Do you own CSL Limited (ASX: CSL) shares?
If you do, then you will no doubt be keen to find out what lies ahead for the biotherapeutics company in October.
What's happening in October?
There are a couple of things of note for shareholders of CSL to look out for.
The first is the payment of the company's final dividend for FY 2023 on 4 October. CSL will be paying A$2.01 per share to investors who were on its share register before they traded ex-dividend on 11 September.
But the main event for shareholders next month will be the company's annual general meeting on 11 October. It's possible that CSL could release a trading update at the event, which will give investors an idea of how it is performing in FY 2024.
There's also potentially a third thing for investors to look out for.
Every year, CSL holds a research and development (R&D) briefing which takes investors through its pipeline. This year's event has not been confirmed, but generally, it takes place in October or November.
Should you buy CSL shares?
A number of leading brokers believe that investors should be buying CSL shares today.
For example, Citi has a buy rating and $325 price target and Morgans has an add rating and $328.20 price target on its shares. These price targets imply a potential upside of approximately 30% for investors over the next 12 months.
While shares have struggled of late, we continue to view CSL as a key portfolio holding and sector pick, offering double-digit recovery in earnings growth as plasma collections increase, new products get approved and influenza vaccine uptake increases around ongoing concerns about respiratory viruses, with shares trading at 25x, a substantial discount (20%) to its long-term average.